|Bid||86.46 x 800|
|Ask||86.85 x 800|
|Day's range||86.36 - 86.92|
|52-week range||73.54 - 95.00|
|Beta (3Y monthly)||0.54|
|PE ratio (TTM)||17.85|
|Forward dividend & yield||2.83 (3.26%)|
|1y target est||101.00|
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Novartis (NVS) reports third-quarter 2019 results.
Novartis' (NVS) phase III REACH2 study on Jakavi for treating patients with steroid-refractory acute graft-versus-host disease meets the primary endpoint of superior overall response rate.
FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.
Biogen strengthens existing efforts in multiple sclerosis and spinal muscular atrophy while making efforts to foray into other neuroscience areas. However, MS is a competitive space. Spinraza may soon face competition.
The FDA approval of the self-administration option and auto-injector of AstraZeneca's (AZN) Fasenra is supported by data from the phase III GRECO study and the phase I AMES study
The FDA approves the label update of Puma Biotech's (PBYI) breast cancer drug Nerlynx in order to add data from the CONTROL study. Stock gains.
J&J (JNJ) settles with two Ohio plaintiffs for $10 million. FDA updates for AstraZeneca (AZN), Merck (MRK) and others and ESMO presentations by big pharma companies in focus.
Roche (RHHBY) gets FDA approval for Rituxan to treat children with two rare blood vessel disorders. The company also extends the offer period to acquire Spark Therapeutics.
Achillion's (ACHN) oral factor D inhibitor, danicopan, receives Breakthrough Therapy designation from the FDA as a treatment option for PNH. Shares up.
Biogen (BIIB) gets CHMP's recommendation to remove pregnancy contraindications from labels of interferon beta treatments, including Plegridy and Avonex
Novartis AG blamed former executives Brian and Allan Kaspar for the manipulation of data behind its $2.1 million gene therapy Zolgensma, saying they either personally manipulated the data or pressured subordinates into doing so. The Kaspar brothers were executives at AveXis, the company that developed the drug and was acquired by Novartis for $8.7 billion last year. Last month, the U.S. Food and Drug Administration said Novartis could face civil or criminal penalties because of the data manipulation and the possibility the company had waited to notify regulators.